{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.117.1.7.1.226","meta":{"source":"https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.226/expansion"},"url":"http://vsac.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226","version":"eCQM Update 2020-05-07","name":"Thrombolytic(t-PA)Therapy","title":"Thrombolytic (t-PA) Therapy","status":"active","date":"2017-07-27","description":"(Clinical Focus: This value set contains concepts that represent medications that are prescribed for thrombolytic (t-PA) therapy for treatment of ischemic stroke.),(Data Element Scope: This value set may use the Quality Data Model (QDM) category related to Medication. The intent of this data element is to identify patients who are administered appropriate thrombolytic (t-PA) therapy for stroke.),(Inclusion Criteria: Includes only relevant concepts associated with RxNorm thrombolytic medications appropriate for stroke treatment consistent with administration by intravenous (IV) route.),(Exclusion Criteria: No exclusions.)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"2020-01","concept":[{"code":"1804799","display":"alteplase 100 MG Injection"},{"code":"1804804","display":"alteplase 50 MG Injection"}]}]}}